scholarly journals Resistance in Pediatric Patients Experiencing Virologic Failure With First-line and Second-line Antiretroviral Therapy

2013 ◽  
Vol 32 (6) ◽  
pp. 644-647 ◽  
Author(s):  
Catherine Orrell ◽  
Julie Levison ◽  
Andrea Ciaranello ◽  
Linda-Gail Bekker ◽  
Daniel R. Kuritzkes ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Pediatric Patients ◽  
Virologic Failure ◽  
Second Line ◽  
First Line ◽  
Second Line Antiretroviral Therapy

scholarly journals Predictors of first line antiretroviral therapy failure and burden of second line antiretroviral therapy

2017 ◽  
Vol 73 (1) ◽  
pp. 5-11 ◽  
Author(s):  
Seema Patrikar ◽  
Subramanian Shankar ◽  
Atul Kotwal ◽  
D.R. Basannar ◽  
Vijay Bhatti ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Second Line ◽  
Therapy Failure ◽  
First Line ◽  
Second Line Antiretroviral Therapy

scholarly journals Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti

2021 ◽  
Vol 8 (12) ◽  
Author(s):  
Samuel Pierre ◽  
Iryna Bocharova ◽  
Catherine Nguyen ◽  
Fabienne Homeus ◽  
Gaetane Julmiste ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Protease Inhibitor ◽  
Tenofovir Disoproxil Fumarate ◽  
Viral Suppression ◽  
Second Line ◽  
First Line ◽  
Second Line Antiretroviral Therapy

Abstract We compared viral suppression rates between patients who continued tenofovir disoproxil fumarate (TDF)/lamivudine (3TC) vs switched to zidovudine (ZDV)/3TC in combination with a boosted protease inhibitor after failure of first-line efavirenz/TDF/3TC. We found higher rates of viral suppression with continued TDF/3TC compared with switching to ZDV/3TC.

scholarly journals Virologic Failure and Second-Line Antiretroviral Therapy in Children in South Africa—The IeDEA Southern Africa Collaboration

2011 ◽  
Vol 56 (3) ◽  
pp. 270-278 ◽  
Author(s):  
Mary-Ann Davies ◽  
Harry Moultrie ◽  
Brian Eley ◽  
Helena Rabie ◽  
Gilles Van Cutsem ◽  
...  
Keyword(s):  
South Africa ◽  
Antiretroviral Therapy ◽  
Southern Africa ◽  
Virologic Failure ◽  
Second Line ◽  
Second Line Antiretroviral Therapy

scholarly journals Virologic Failure of Protease Inhibitor-Based Second-Line Antiretroviral Therapy without Resistance in a Large HIV Treatment Program in South Africa

PLoS ONE ◽  
2012 ◽  
Vol 7 (3) ◽  
pp. e32144 ◽  
Author(s):  
Julie H. Levison ◽  
Catherine Orrell ◽  
Sébastien Gallien ◽  
Daniel R. Kuritzkes ◽  
Naishin Fu ◽  
...  
Keyword(s):  
South Africa ◽  
Antiretroviral Therapy ◽  
Protease Inhibitor ◽  
Treatment Program ◽  
Virologic Failure ◽  
Hiv Treatment ◽  
Second Line ◽  
Second Line Antiretroviral Therapy

scholarly journals Diverse Human Immunodeficiency Virus–1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line Antiretroviral Therapy in Resource-limited Settings

2019 ◽  
Vol 71 (7) ◽  
pp. e170-e177 ◽  
Author(s):  
Carole L Wallis ◽  
Michael D Hughes ◽  
Justin Ritz ◽  
Raquel Viana ◽  
Carlos Silva de Jesus ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Drug Resistance ◽  
Antiretroviral Therapy ◽  
Virologic Failure ◽  
Cd4 T Cell ◽  
Second Line ◽  
Drug Classes ◽  
Immunodeficiency Virus ◽  
Third Line ◽  
Second Line Antiretroviral Therapy

Abstract Background Human immunodeficiency virus (HIV) drug resistance profiles are needed to optimize individual patient management and to develop treatment guidelines. Resistance profiles are not well defined among individuals on failing second-line antiretroviral therapy (ART) in low- and middle-income countries (LMIC). Methods Resistance genotypes were performed during screening for enrollment into a trial of third-line ART (AIDS Clinical Trials Group protocol 5288). Prior exposure to both nucleoside reverse transcriptase inhibitors (NRTIs) and non-NRTIs and confirmed virologic failure on a protease inhibitor–containing regimen were required. Associations of drug resistance with sex, age, treatment history, plasma HIV RNA, nadir CD4+T-cell count, HIV subtype, and country were investigated. Results Plasma HIV genotypes were analyzed for 653 screened candidates; most had resistance (508 of 653; 78%) to 1 or more drugs. Genotypes from 133 (20%) showed resistance to at least 1 drug in a drug class, from 206 (32%) showed resistance to at least 1 drug in 2 drug classes, and from 169 (26%) showed resistance to at least 1 drug in all 3 commonly available drug classes. Susceptibility to at least 1 second-line regimen was preserved in 59%, as were susceptibility to etravirine (78%) and darunavir/ritonavir (97%). Susceptibility to a second-line regimen was significantly higher among women, younger individuals, those with higher nadir CD4+ T-cell counts, and those who had received lopinavir/ritonavir, but was lower among prior nevirapine recipients. Conclusions Highly divergent HIV drug resistance profiles were observed among candidates screened for third-line ART in LMIC, ranging from no resistance to resistance to 3 drug classes. These findings underscore the need for access to resistance testing and newer antiretrovirals for the optimal management of third-line ART in LMIC.

First-line and second-line antiretroviral therapy

The Lancet ◽  
2004 ◽  
Vol 364 (9431) ◽  
pp. 329 ◽  
Author(s):  
Alexandra Calmy ◽  
Fernando Pascual ◽  
Nathan Ford
Keyword(s):  
Antiretroviral Therapy ◽  
Second Line ◽  
First Line ◽  
Second Line Antiretroviral Therapy
Sign in / Sign up

Export Citation Format

Share Document